Steven Cohen’s Autolus Therapeutics AUTL Stock Holding History

Steven Cohen’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$114K	Sell	71,227 -355,756	-83%	-$558K	﹤0.01%	3676
2026 Q1	$589K	Buy	426,983 +121,624	+40%	+$185K	﹤0.01%	3050
2025 Q4	$608K	Buy	+305,359	New	+$469K	﹤0.01%	3144
2025 Q3	–	Sell	-71,400	Closed	-$163K	–	2308
2025 Q2	$163K	Buy	71,400 +36,755	+106%	+$60.8K	﹤0.01%	2018
2025 Q1	$53.7K	Sell	34,645 -212,444	-86%	-$431K	﹤0.01%	1952
2024 Q4	$581K	Buy	+247,089	New	+$835K	﹤0.01%	1630
2024 Q2	–	Sell	-37,300	Closed	-$238K	–	1855
2024 Q1	$238K	Buy	+37,300	New	+$233K	﹤0.01%	1851
2020 Q2	–	Sell	-124,463	Closed	-$746K	–	800
2020 Q1	$746K	Sell	124,463 -191,341	-61%	-$1.77M	0.01%	631
2019 Q4	$4.17M	Buy	315,804 +238,150	+307%	+$3.12M	0.02%	526
2019 Q3	$964K	Buy	+77,654	New	+$1.03M	0.01%	695

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Steven Cohen's AUTL Position: Q2 2026 in Review

Steven Cohen reduced its Autolus Therapeutics (AUTL) stake by 83% in Q2 2026, selling an estimated $558K and leaving 71,227 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #3676.

Steven Cohen first reported a position in AUTL in Q3 2019 and has held it in 10 quarters since. The position peaked at $4.17M in Q4 2019. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

Steven Cohen held 71,227 shares of Autolus Therapeutics worth $114K as of Q2 2026.
Steven Cohen sold 355,756 Autolus Therapeutics shares in Q2 2026, an estimated $558K.
Autolus Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #3676 holding.
Steven Cohen first reported a position in Autolus Therapeutics in Q3 2019 and has held it in 10 quarters since.
Steven Cohen's Autolus Therapeutics position peaked at $4.17M in Q4 2019.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.